Company news
Tetra Bio-pharma Inc. (OTC:TBPMQ) news
Tetra Bio-pharma Inc. news releases on 6ix. Latest, May 18, 2021: Tetra Bio-Pharma Inc. Announces Changes to its Board of Directors and the Filing…
Press releases — page 2
Tetra Bio-Pharma Inc. Announces Changes to its Board of Directors and the Filing of a Supplement to its Management Information Circular
May 18, 2021
Tetra Bio-Pharma Announces Closing of Bought Deal Offering
May 17, 2021
NEXT SUPER STOCKS on The Move: FansUnite, Reliq Health Tech, Hapbee, and Tetra Bio-Pharma
May 12, 2021
Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain
May 10, 2021
Tetra Bio-Pharma Announces $10 Million "Bought Deal" Public Offering
May 10, 2021
NEXT SUPER STOCKS on The Move: Tetra Bio-Pharma, Relay Medical, Victory Square Technologies, and Red Light Holland
May 7, 2021
Tetra Bio-Pharma Announces Start of the REBORN1(C) Clinical Trial
May 5, 2021
Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios
May 4, 2021
Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada
May 2, 2021
Next Super Stocks on The Move: Tetra Bio-Pharma, ESE Entertainment, Red Light Holland, and Skylight Health. Innovation Leaders in E-Sports, Healthcare, Psychedelics, and Pharma Targeting Billion Dollar Markets.
April 29, 2021
Tetra Bio-Pharma Submits Request for Scientific Advice to Malta Medicines Authority
April 27, 2021
Tetra Bio-Pharma Provides an Update on its U.S. REBORN1 Clinical Trial
April 22, 2021
Tetra Bio-Pharma Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis
April 14, 2021
Tetra Bio-Pharma Provides Update on Its New Drug Submission Application in Canada
April 13, 2021
NEXT SUPER STOCKS Addressing Multi-Billion Dollar Healthcare Markets: Tetra Bio-Pharma, Relay Medical, Skylight Health, Reliq HealthTech
March 31, 2021
Tetra Bio-Pharma Inc. Announces $10 Million Bought Deal Offering of Units
February 22, 2021
Tetra Bio-Pharma Inc. Announces Closing of Non-Brokered Private Placement
February 3, 2021
Tetra Bio-Pharma Inc. Announces a Non-Brokered Private Placement
January 27, 2021
Tetra Bio-Pharma Files New Drug Submission for REDUVO(TM) in Canada
December 29, 2020
Tetra Bio-Pharma Provides Update on Recent Milestones
November 15, 2020
Tetra Bio-Pharma Inc. Acquires Common Shares of Mondias Natural Products Inc.
November 2, 2020
Tetra Bio Pharma Announces Divestiture of Lumiera Health Innovation Inc.
October 27, 2020
IntelGenx Enters Into Amended and Restated License Agreement with Tetra Bio-Pharma for Adversa® Mucoadhesive Delivery Technology for Dronabinol
October 21, 2020
Tetra Bio-Pharma Acquires Exclusive Global Technology Rights to a Mucoadhesive Delivery Technology Called Adversa(R) for its PPP-002 (dronabinol) drug candidate from IntelGenx
October 20, 2020
Tetra Bio-Pharma Announces Positive Results in Animal Studies for Treatment of Hyperinflammatory Lung Injury
October 19, 2020
Tetra Bio-Pharma to Present at Alpha Bronze Virtual Town Hall
October 5, 2020
Tetra Bio-Pharma (TBP) Acquires Dronabinol Soft Gel Capsules Exclusive Canadian Distribution Rights to Establish a Strong Commercial Presence in Canada and Accelerate its Profitability
September 29, 2020
Dania Scott Joins Tetra Bio-Pharma as Senior Vice President Commercial Strategy
September 3, 2020
Tetra Bio-Pharma Announces Plenitude Clinical Trial is Initiated
September 1, 2020
Tetra Bio-Pharma Announces Expected Effective Date of Listing on TSX of its Common Shares and Warrants
July 30, 2020
Tetra Bio-Pharma and Altus Formulation Form New Company "TALLC" to Exploit TA-A001
June 2, 2020
Tetra Bio-Pharma Provides HCC011 Program Update Following Type B Meeting with USA FDA
June 1, 2020
Tetra Bio-Pharma Announces Closing of Public Offering
May 22, 2020
Tetra Bio-Pharma Announces Sizing of Public Offering
May 15, 2020
Tetra Bio-Pharma Announces Overnight Marketed Offering
May 14, 2020
Tetra Bio-Pharma Provides PPP003 Inflammatory Cytokine Reduction Drug Program
May 5, 2020
Tetra Receives its 4th FDA Orphan Drug Designation
April 15, 2020
Tetra Receives FDA Orphan Drug Designation for its Ophthalmic Clinical Program
April 14, 2020
Tetra BioPharma Confirms QIXLEEF Clinical Site Receives Renewal of DEA Schedule 1 License
April 13, 2020
Tetra Offers Pro-Bono Regulatory and Quality Assurance Expertise to Companies Developing COVID-19 Solutions
April 8, 2020
Tetra Biopharma Confirms Type B Meeting Date With FDA Regarding HCC011
April 6, 2020
Tetra Bio-Pharma Maps Out Cannabinoid Metabolites in Humans Following Inhalation of QIXLEEF
April 2, 2020
Tetra Bio Pharma Announces Filing of Final Base Shelf Prospectus for up to $50 Million of Securities
April 1, 2020
Tetra Bio-Pharma Announces Filing of Restated Financial Statements and MD&A
March 30, 2020
Tetra Biopharma Survey Validates Primary Endpoint of SERENITY© Clinical Trial
March 26, 2020
Tetra Bio-Pharma Provides Management Update on COVID-19
March 23, 2020
Tetra Bio-Pharma Engages Alpha Bronze LLC as investor relations and public relations firm
March 6, 2020
Tetra Bio-Pharma Enters into Co-Development Agreement with MAKScientific
February 27, 2020
Tetra Bio-Pharma Provides Additional Information on CAUMZ Following Type B Meeting with USA FDA
February 25, 2020
Tetra Bio-Pharma Provides Additional Information on QIXLEEF Following Letter of Advice & Type B Meeting with USA FDA
February 24, 2020